Video Shorts

Will Neoadjuvant Therapy Reshape the Future of CRC Management?

The Potential Role of the SERENA-6 Data in Breast Oncology

HPV Prevention and Screening Gaps Continue to Drive Anal Cancer Risk

Luspatercept and Frontline Treatment Decisions in Lower-Risk MDS

OncLive News Roundup for the Week of 3/22

BOOM Provides Consensus on Periprosthetic Joint Infection Management in Orthopedic Oncology—but Evidence Gaps Remain

The Evolution of Axillary Lymph Node Dissection Practices in Breast Cancer

What the FDA Approval of Daratumumab Plus Teclistamab Means for R/R Myeloma Care

Clinical Equipose When Recommending Individual Clinical Trials

Robotics, Cost, and Caution: What’s Actually Advancing Surgical Care in CRC?

Precision Medicine Remains the Priority During Multiple Myeloma Awareness Month

Missed Signs and Screening Gaps: Why Is Early CRC Detection Falling Short?

Elucidating the Next Steps After EV-Pembro in Urothelial Carcinoma

Exploring the Evolution of ctDNA Testing in Breast Cancer

PD-L1 As a Prognostic Biomarker in Penile Cancer

Emphasizing the Importance of Considering Different Patient Priorities

Anal Cancer Care Is Entering a New Era of Precision Medicine and Immunotherapy Use

Examining Results From the ENVISION Trial in NMIBC

Long-Term Goal-Based TKI Treatment Decision-Making for Patients With CML

Targeted Therapies Continue to Reshape Third-Line Treatment Sequencing Decisions in CRC

ASH Guidelines Provide Key Recommendations in AYA ALL Management

Local vs Systemic Therapy for CNS Metastases in Lung Cancer

Previewing Future Directions for Investigating RSK Inhibition in Breast Cancer

Utilizing MRD Status in Acute Lymphoblastic Leukemia Management

Of mice but not men. Problems of the randomized clinical trial

Examining Pasritamig Plus Docetaxel in mCRPC

Peptide Receptor Radionucleotide Therapies Gain Momentum in NETs

OncLive News Roundup for the Week of 3/8

Ethics and Identity in Oncology: Clinician vs Investigator

Recapping Top Coverage from MBCC 2026!